Johnson & Johnson (JNJ)
| Market Cap | 486.51B |
| Revenue (ttm) | 92.15B |
| Net Income (ttm) | 25.12B |
| Shares Out | 2.41B |
| EPS (ttm) | 10.35 |
| PE Ratio | 19.51 |
| Forward PE | 18.11 |
| Dividend | $5.20 (2.58%) |
| Ex-Dividend Date | Nov 25, 2025 |
| Volume | 7,785,011 |
| Open | 202.98 |
| Previous Close | 202.48 |
| Day's Range | 200.81 - 203.45 |
| 52-Week Range | 140.68 - 207.81 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 199.40 (-1.25%) |
| Earnings Date | Jan 21, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $199.4, which is a decrease of -1.25% from the latest price.
News
Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal Patients with this t...
Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades
Shares of Teradyne advanced sharply as investors cheered the company's robust earnings and outlook for Teradyne's artificial intelligence compute testing business. We initiated a position in this cust...
16 Quality Stocks to Own for a Volatile Market
The S&P 500 has staged an impressive rebound, but is in for more swings.
Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)
Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive
3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio
Intuitive Surgical shows why now is a good time to consider buying surgical-robot competitor Medtronic. Eli Lilly helps explain why down-and-out drugmaker Pfizer could be worth a close look for long-t...
2 Top Dividend Stocks to Buy and Hold
Bristol Myers Squibb and Johnson & Johnson have had a tough past few years due to several factors. Both companies are looking to right the ship thanks to new product launches.
Best Dividend Aristocrats For December 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,...
Dogs Of The Dow Continue Outperforming Broader Market
Through the end of November, the year-to-date total return of the Dogs of the Dow equals 20.96%, outpacing the Dow Jones Industrial Average return of 13.86% and outpacing the broader S&P 500 Index ret...
Wasatch Global Value Fund Q3 2025 Performance Review
The Wasatch Global Value Fund - Investor Class gained 6.36% in the third quarter of 2025, outperforming the MSCI All Country World Value Index, which added 6.13%. Leading contributors to the Fund's pe...
3 Superb Dividend Stocks to Hold for the Next 20 Years
Johnson & Johnson is a financial fortress with a solid pipeline and portfolio. Coca-Cola has an asset-light model that drives its profitability.
Have $2,000 to Invest? Here Are 4 of My Favorite Dividend Stocks for the Next 5 Years
Pfizer and Johnson & Johnson are healthcare leaders and faithful dividend payers. Home Depot is facing a difficult operating environment, but its core business remains strong.
JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?
The pharmaceutical powerhouse Johnson & Johnson (NYSE: JNJ) has significantly outperformed its competitor Pfizer (NYSE: PFE) this year. JNJ's stock has risen by almost 45%, whereas PFE has declined by...
1 Reason Why Shares of Johnson & Johnson Are Surging This Month
Last month, Johnson & Johnson surged following a well-received quarterly earnings release. Despite a sluggish start to November, a spate of positive news has since sent the healthcare stock's shares t...
Why Johnson & Johnson's Share Price Is Popping This Month
J&J beat Wall Street estimates on sales and profits in the third quarter. The company recently announced the acquisition of a biotech with an innovative cancer treatment.
Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today announced its fourth major Vida portfolio acquisition of 2025, capping an unprecedent...
Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Johnson & Johnson ( JNJ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 10:40 AM EST Company Participants Candice Long - Worldwide Vice President of Immunology David Lee - Global T...
Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion
Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a deal that bolsters the healthcare giant's oncology pipeline.
Halda Therapeutics Announces Acquisition by Johnson & Johnson
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics announced today that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire Halda for $3.05 ...
J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion
Johnson & Johnson said on Monday it would buy Halda Therapeutics for $3.05 billion in cash, expanding its presence in solid tumors and prostate cancer treatments.
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety prof...
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage b...
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.